TET2 and mature T-cell and NK-cell non-Hodgkin lymphoma: Specifically, TET2 has been frequently reported to be mutated in hematological malignancies (85), including angioimmunoblastic T cell lymphoma (AITL) (86–88) and peripheral T cell lymphoma, non-otherwise specified (PTCL-NOS) (89).